Figure 5 compares mRNA expression levels of TMEM106B between cognitively unimpaired individuals (CU) and individuals with progressive supranuclear palsy (PSP), pathological aging (PA) and Alzheimer’s disease (AD) from the Mayo clinic cohort. This evidence concerns the gene TMEM106B and early-onset autosomal dominant Alzheimer disease.